Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

19 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Anticancer activities of histone deacetylase inhibitors.
Bolden JE, Peart MJ, Johnstone RW. Bolden JE, et al. Nat Rev Drug Discov. 2006 Sep;5(9):769-84. doi: 10.1038/nrd2133. Nat Rev Drug Discov. 2006. PMID: 16955068 Review.
HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses.
Bolden JE, Shi W, Jankowski K, Kan CY, Cluse L, Martin BP, MacKenzie KL, Smyth GK, Johnstone RW. Bolden JE, et al. Cell Death Dis. 2013 Feb 28;4(2):e519. doi: 10.1038/cddis.2013.9. Cell Death Dis. 2013. PMID: 23449455 Free PMC article.
Molecular and biologic analysis of histone deacetylase inhibitors with diverse specificities.
Newbold A, Matthews GM, Bots M, Cluse LA, Clarke CJ, Banks KM, Cullinane C, Bolden JE, Christiansen AJ, Dickins RA, Miccolo C, Chiocca S, Kral AM, Ozerova ND, Miller TA, Methot JL, Richon VM, Secrist JP, Minucci S, Johnstone RW. Newbold A, et al. Among authors: bolden je. Mol Cancer Ther. 2013 Dec;12(12):2709-21. doi: 10.1158/1535-7163.MCT-13-0626. Epub 2013 Oct 3. Mol Cancer Ther. 2013. PMID: 24092806 Free article.
The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy.
Ellis L, Bots M, Lindemann RK, Bolden JE, Newbold A, Cluse LA, Scott CL, Strasser A, Atadja P, Lowe SW, Johnstone RW. Ellis L, et al. Blood. 2009 Jul 9;114(2):380-93. doi: 10.1182/blood-2008-10-182758. Epub 2009 Apr 21. Blood. 2009. PMID: 19383971 Free PMC article.
Enhancing the apoptotic and therapeutic effects of HDAC inhibitors.
Frew AJ, Johnstone RW, Bolden JE. Frew AJ, et al. Cancer Lett. 2009 Aug 8;280(2):125-33. doi: 10.1016/j.canlet.2009.02.042. Epub 2009 Apr 8. Cancer Lett. 2009. PMID: 19359091 Review.
Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist.
Frew AJ, Lindemann RK, Martin BP, Clarke CJ, Sharkey J, Anthony DA, Banks KM, Haynes NM, Gangatirkar P, Stanley K, Bolden JE, Takeda K, Yagita H, Secrist JP, Smyth MJ, Johnstone RW. Frew AJ, et al. Proc Natl Acad Sci U S A. 2008 Aug 12;105(32):11317-22. doi: 10.1073/pnas.0801868105. Epub 2008 Aug 6. Proc Natl Acad Sci U S A. 2008. PMID: 18685088 Free PMC article.
Identification of novel Ras-cooperating oncogenes in Drosophila melanogaster: a RhoGEF/Rho-family/JNK pathway is a central driver of tumorigenesis.
Brumby AM, Goulding KR, Schlosser T, Loi S, Galea R, Khoo P, Bolden JE, Aigaki T, Humbert PO, Richardson HE. Brumby AM, et al. Genetics. 2011 May;188(1):105-25. doi: 10.1534/genetics.111.127910. Epub 2011 Mar 2. Genetics. 2011. PMID: 21368274 Free PMC article.
BRD4 Connects Enhancer Remodeling to Senescence Immune Surveillance.
Tasdemir N, Banito A, Roe JS, Alonso-Curbelo D, Camiolo M, Tschaharganeh DF, Huang CH, Aksoy O, Bolden JE, Chen CC, Fennell M, Thapar V, Chicas A, Vakoc CR, Lowe SW. Tasdemir N, et al. Among authors: bolden je. Cancer Discov. 2016 Jun;6(6):612-29. doi: 10.1158/2159-8290.CD-16-0217. Epub 2016 Apr 20. Cancer Discov. 2016. PMID: 27099234 Free PMC article.
The BTB-zinc finger transcription factor abrupt acts as an epithelial oncogene in Drosophila melanogaster through maintaining a progenitor-like cell state.
Turkel N, Sahota VK, Bolden JE, Goulding KR, Doggett K, Willoughby LF, Blanco E, Martin-Blanco E, Corominas M, Ellul J, Aigaki T, Richardson HE, Brumby AM. Turkel N, et al. Among authors: bolden je. PLoS Genet. 2013;9(7):e1003627. doi: 10.1371/journal.pgen.1003627. Epub 2013 Jul 18. PLoS Genet. 2013. PMID: 23874226 Free PMC article.
19 results
Jump to page
Feedback